p38 Mitogen-Activated Protein Kinase (MAPK) increases arginase activity and contributes to endothelial dysfunction in corpora cavernosa from angiotensin-II-treated mice

Journal of Sexual Medicine

Volumn 7, Issue 12, 2010, Pages 3857-3867

  Toque, Haroldo A ^a   Romero, Maritza J ^a   Tostes, Rita C ^a   Shatanawi, Alia ^a   Chandra, Surabhi ^a   Carneiro, Zidonia N ^a   Inscho, Edward W ^a   Webb, Robert Clinton ^a   Caldwell, Ruth B ^a   Caldwell, Robert William ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Angiotensin II; Arginase Activity; Erectile Dysfunction; Nitric Oxide; P38 MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCHOLINE; ANGIOTENSIN II; ARGINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; ELECTROSTIMULATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SYSTOLIC BLOOD PRESSURE;

EID: 78649844792     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01996.x     Document Type: Article

References (50)

1. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001;53:417-50.
2. Champion HC, Bivalacqua TJ, Hyman AL, Ignarro LJ, Hellstrom WJ, Kadowitz PJ. Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci 1999;96:11648-52.
3. Park K, Kim SW, Rhu KS, Paick JS. Chronic administration of an oral Rho kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model. J Sex Med 2006;3:996-1003.
4. Xie D, Odronic SI, Wu F, Pippen AM, Donatucci CF, Annex BH. A mouse model of hypercholesterolemia-induced erectile dysfunction. J Sex Med 2007;4:898-907.
5. Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2003;52:2353-62.
6. Toque HA, Iddings J, Xu Z, Tostes RC, Webb RC, Caldwell RB, Caldwell RW. Arginase II deletion increases corpora cavernosa relaxation in diabetic mice. Faseb J 2010;24:lb514 (Abstract).
7. Barassi A, Colpi GM, Piediferro G, Dogliotti G, D'Eril GV, Corsi MM. Oxidative stress and antioxidant status in patients with erectile dysfunction. J Sex Med 2009;6:2820-5.
8. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC. Increased expression of arginase II in human diabetic corpus cavernosum: In diabetic-associated erectile dysfunction. Biochem Biophys Res Commun 2001;283:923-7.
9. Bivalacqua TJ, Burnett AL, Hellstrom WJ, Champion HC. Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: Influence of in vivo gene therapy of anti-arginase. Am J Physiol Heart Circ Physiol 2007;292:H1340-51.
10. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, Burke S, Shoukas AA, Nyhan D, Champion HC, Hare JM. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003;108:2000-6.
11. Gao X, Xu X, Belmadani S, Park Y, Tang Z, Feldman AM, Chilian WM, Zhang C. TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 2007;27:1269-75.
12. Numao N, Masuda H, Sakai Y, Okada Y, Kihara K, Azuma H. Roles of attenuated neuronal nitric-oxide synthase protein expression and accelerated arginase activity in impairing neurogenic relaxation of corpus cavernosum in aged rabbits. BJU Int 2007;99:1495-9.
13. Mori M, Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun 2000;275:715-9.
14. Vockley JG, Jenkinson CP, Shukla H, Kern RM, Grody WW, Cederbaum SD. Cloning and characterization of the human type II arginase gene. Genomics 1996;38:118-23.
15. Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 2002;22:87-105.
16. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, Caldwell RB, Caldwell RW. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008;102:95-102.
17. Cox JD, Kim NN, Traish AM, Christianson DW. Arginase-boronic acid complex highlights a physiological role in erectile function. Nat Struct Biol 1999;6:1043-7.
18. Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res 2002;35:1001-15.
19. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997;157:1920-5.
20. Becker AJ, Uckert S, Stief CG, Truss MC, Machtens S, Scheller F, Knapp WH, Hartmann U, Jonas U. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology 2001;57:193-8.
21. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996;98:2572-9.
22. Jin L, Lagoda G, Leite R, Webb RC, Burnett AL. NADPH oxidase activation: A mechanism of hypertension-associated erectile dysfunction. J Sex Med 2008;5:544-51.
23. Touyz RM, Deschepper C, Park JB, He G, Chen X, Neves MF, Virdis A, Schiffrin EL. Inhibition of mitogen-activated protein/extracellular signal-regulated kinase improves endothelial function and attenuates AngII-induced contractility of mesenteric resistance arteries from spontaneously hypertensive rats. J Hypertens 2002;20:1127-34.
24. Nakashima H, Suzuki H, Ohtsu H, Chao JY, Utsunomiya H, Frank GD, Eguchi S. Angiotensin II regulates vascular and endothelial dysfunction: Recent topics of angiotensin II type-1 receptor signaling in the vasculature. Curr Vasc Pharmacol 2006;4:67-78.
25. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001;44:1973-88.
26. Purves T, Middlemas A, Agthong S, Jude EB, Boulton AJ, Fernyhough P, Tomlinson DR. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J 2001;15:2508-14.
27. Costanzo A, Moretti F, Burgio VL, Bravi C, Guido F, Levrero M, Puri PL. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 2003;195:402-10.
28. Nangle MR, Cotter MA, Cameron NE. Correction of nitrergic neurovascular dysfunction in diabetic mouse corpus cavernosum by p38 mitogen-activated protein kinase inhibition. Int J Impot Res 2006;18:258-63.
29. Sugden PH, Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 1998;83:345-52.
30. Viedt C, Soto U, Krieger-Brauer HI, Fei J, Elsing C, Kübler W, Kreuzer J. Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: Involvement of p22phox and reactive oxygen species. Arterioscler Thromb Vasc Biol 2000;20:940-8.
31. Meloche S, Landry J, Huot J, Houle F, Marceau F, Giasson E. p38 MAP kinase pathway regulates angiotensin II-induced contraction of rat vascular smooth muscle. Am J Physiol Heart Circ Physiol 2000;279:H741-51.
32. Zhang GX, Kimura S, Nishiyama A, Shokoji T, Rahman M, Abe Y. ROS during the acute phase of Ang II hypertension participates in cardiovascular MAPK activation but not vasoconstriction. Hypertension 2004;43:117-24.
33. Widder J, Behr T, Fraccarollo D, Hu K, Galuppo P, Tas P, Angermann CE, Ertl G, Bauersachs J. Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent. Cardiovasc Res 2004;63:161-7.
34. Bao W, Behm DJ, Nerurkar SS, Ao Z, Bentley R, Mirabile RC, Johns DG, Woods TN, Doe CP, Coatney RW, Ohlstein JF, Douglas SA, Willette RN, Yue TL. Effects of p38 MAPK inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol 2007;49:362-8.
35. Olzinski AR, McCafferty TA, Zhao SQ, Behm DJ, Eybye ME, Maniscalco K, Bentley R, Frazier KS, Milliner CM, Mirabile RC, Coatney RW, Willette RN. Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: Role of systemic blood pressure and endothelial protection. Cardiovasc Res 2005;66:170-8.
36. Stempin CC, Tanos TB, Coso OA, Cerbán FM. Arginase induction promotes Trypanosoma cruzi intracellular replication in Cruzipain-treated J774 cells through the activation of multiple signaling pathways. Eur J Immunol 2004;34:200-9.
37. Liscovsky MV, Ranocchia RP, Gorlino CV, Alignani DO, Morón G, Maletto BA, Pistoresi-Palencia MC. Interferon-gamma priming is involved in the activation of arginase by oligodeoxinucleotides containing CpG motifs in murine macrophages. Immunology 2009;128:159-69.
38. Shatanawi A, Romero MJ, Iddings JA, Caldwell RB, Caldwell RW. Angiotensin II elevates endothelial arginase activity via RhoA/MAPK pathways. Faseb J 2010;24:959.2 (Abstract).
39. Komers R, Schutzer W, Xue H, Oyama TT, Lindsley JN, Anderson S. Effects of p38 mitogen-activated protein kinase inhibition on blood pressure, renal hemodynamics, and renal vascular reactivity in normal and diabetic rats. Transl Res 2007;150:343-9.
40. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 1998;273:15022-9.
41. Jiang B, Xu S, Hou X, Pimentel DR, Cohen RA. Angiotensin II differentially regulates interleukin-1-beta-inducible NO synthase (iNOS) and vascular cell adhesion molecule-1 (VCAM-1) expression: Role of p38 MAPK. J Biol Chem 2004;279:20363-8.
42. Su Z, Zimpelmann J, Burns KD. Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 2006;69:2212-8.
43. Beltrán AE, Briones AM, García-Redondo AB, Rodríguez C, Miguel M, Alvarez Y, Alonso MJ, Martínez-González J, Salaices M. p38 MAPK contributes to angiotensin II-induced COX-2 expression in aortic fibroblasts from normotensive and hypertensive rats. J Hypertens 2009;27:142-54.
44. Ge B, Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, Luo Y, Han J. MAPKK-independent activation of p38 alpha mediated by TAB1-dependent autophosphorylation of p38 alpha. Science 2002;295:1291-4.
45. Musicki B, Burnett AL. eNOS function and dysfunction in the penis. Exp Biol Med (Maywood) 2006;231:154-65.
46. Weerackody RP, Welsh DJ, Wadsworth RM, Peacock AJ. Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. Am J Physiol Heart Circ Physiol 2009;296:H1312-20.
47. Zhou S, Bachem MG, Seufferlein T, Li Y, Gross HJ, Schmelz A. Low intensity pulsed ultrasound accelerates macrophage phagocytosis by a pathway that requires actin polymerization, Rho, and Src/MAPKs activity. Cell Signal 2008;20:695-704.
48. Chandra S, Romero MJ, Shatanawi A, Caldwell RB, Caldwell RW. Peroxynitrite and hydrogen peroxide increase arginase activity through the RhoA/Rho kinase (RAK) pathway. Faseb J 2010;24:959.4 (Abstract).
49. Okon EB, Szado T, Laher I, McManus B, Van Breemen C. Augmented contractile response of vascular smooth muscle in a diabetic mouse model. J Vasc Res 2003;40:520-30.
50. Jin LM. Angiotensin II signaling and its implication in erectile dysfunction. J Sex Med 2009;3:302-10.